Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial

17 Jul 2017

Abstract excerpt

BACKGROUND: Aging frailty, characterized by decreased physical and immunological functioning, is associated with stem cell depletion. Human allogeneic mesenchymal stem cells (allo-hMSCs) exert immunomodulatory effects and promote tissue repair. METHODS: This is a randomized, double-blinded, dose-finding study of intravenous allo-hMSCs (100 or 200-million [M]) vs placebo delivered to patients (n = 30, mean age...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Frailty in Older Adults
Share to Mesenchymal stem cell research
Share to Muscle Physiology and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28977399
DOI: 10.1093/gerona/glx137

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical TrialPMID 28977399Read ↗

Cellular senescence and frailty: a comprehensive insight into the causal links.Semantic proximity Read ↗

Running on empty: Exploring stem cell exhaustion in geriatric musculoskeletal diseaseSemantic proximity Read ↗

Clinical Trials Targeting AgingSemantic proximity Read ↗

Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic Malignancy.Semantic proximity Read ↗

Restoring aged stem cell functionality: Current progress and future directions.Semantic proximity Read ↗

Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study.Semantic proximity Read ↗

Engineering Mesenchymal Stem Cells to Extend Healthspan: Therapeutic Potential, Challenges, and Future SolutionsSemantic proximity Read ↗

REPROGRAM: REsilience PROmotion with GeRoprotectors: AssessMent of biological effect. Rationale and protocol for a trial of biological effectSemantic proximity Read ↗

Effect of dietary omega-3 fatty acid supplementation on frailty-related phenotypes in older adults: a systematic review and meta-analysis protocol.Semantic proximity Read ↗

Association between Immunosenescence, Mitochondrial Dysfunction and Frailty Syndrome in Older AdultsSemantic proximity Read ↗

Critical Illness and the Frailty Syndrome: Mechanisms and Potential Therapeutic Targets.Semantic proximity Read ↗

Exercise as an intervention for frailty.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.